Investor Portal

News

Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Neovascular Wet Age-Related Macular Degeneration

Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Neovascular Wet Age-Related Macular Degeneration Two-year results from CEDAR and SEQUOIA demonstrate that vision gains observed after one year with every 8-week and every 12-week dosing were maintained in the second year Abicipar [...]

2019-10-22T11:02:49+01:00October 14th, 2019|All News, Company News, Previous Sectors|

V-Wave Receives Second FDA Breakthrough Device Designation: Interatrial Shunt for Pulmonary Arterial Hypertension

V-Wave Receives Second FDA Breakthrough Device Designation: Interatrial Shunt for Pulmonary Arterial Hypertension V-Wave’s two distinct FDA Breakthrough Device Designations illustrate the company’s dedication to innovation and improving outcomes for two debilitating diseases – Heart Failure and Pulmonary Arterial Hypertension CAESAREA, Israel, September 12, 2019 – V-Wave Ltd., [...]

2019-10-10T10:05:26+01:00September 13th, 2019|All News, Company News|

Allergan & Molecular Partners Announce Acceptance of U.S. FDA Biologics License Application and Validation of EMA Marketing Authorisation

Allergan & Molecular Partners Announce Acceptance of U.S. FDA Biologics License Application and Validation of EMA Marketing Authorisation The acceptance and authorisation are for Abicipar pegol in patients with neovascular (wet) age-related macular degeneration Filing includes data from two Phase 3 trials which evaluated the safety and efficacy [...]

2019-10-10T10:53:56+01:00September 9th, 2019|All News, Company News, Previous Sectors|

Endeavour Vision accelerates investments in Switzerland and the US – an interview with AGEFI

Endeavour Vision accelerates investments in Switzerland and the US – an interview with AGEFI Endeavour Vision Founding Partners Damien Tappy and Bernard Vogel spoke to AGEFI about the next fund and the firm’s investment approach. Read the article from AGEFI here Medtech: Endeavour Vision accélère ses investissements en [...]

2019-10-11T12:00:45+01:00September 9th, 2019|All News, Blog|

Relievant Announces Publication of Positive Results from Multi-Center Study of the Intracept® Procedure in Real-world Setting for Patients with Chronic Low Back Pain

Relievant Announces Publication of Positive Results from Multi-Center Study of the Intracept® Procedure in Real-world Setting for Patients with Chronic Low Back Pain MINNEAPOLIS – August 27, 2019 – Relievant Medsystems, a privately-held medical device company transforming the treatment of Chronic Low Back Pain (CLBP), today announced the [...]

2019-10-10T10:56:03+01:00August 27th, 2019|All News, Company News|

V-Wave’s Interatrial Shunt Receives FDA Breakthrough Device Designation for Heart Failure

V-Wave’s Interatrial Shunt Receives FDA Breakthrough Device Designation for Heart Failure CAESAREA, Israel, Aug. 15, 2019 — V-Wave Ltd., a privately held medical device company developing novel implantable interatrial shunt devices, today announced that the U.S. Food and Drug Administration (FDA) has just granted the company a Breakthrough Device [...]

2019-10-10T09:43:56+01:00August 19th, 2019|All News, Company News|

Molecular Partners’ strategic partner Allergan announces that EMA has validated the marketing authorisation application for abicipar

Molecular Partners’ strategic partner Allergan announces that EMA has validated the marketing authorisation application for abicipar CAESAREA, Israel, Aug. 15, 2019 — V-Wave Ltd., a privately held medical device company developing novel implantable interatrial shunt devices, today announced that the U.S. Food and Drug Administration (FDA) has just granted [...]

2019-10-10T09:43:07+01:00August 7th, 2019|All News, Company News, Previous Sectors|

Interview with Rob Barmann, Senior Investment Director at Endeavour Vision

Interview with Rob Barmann, Senior Investment Director at Endeavour Vision Previously Vice President, Corporate Business Development at Boston Scientific. Rob, you joined Endeavour Vision after 15 years working at Boston Scientific, can you summarise your role there? My job was to assess and execute business development transactions including acquisitions, [...]

2019-10-10T09:41:58+01:00July 24th, 2019|All News, Blog|

Interview with Kevin Hykes, President & CEO at Relievant

Interview with Kevin Hykes, President & CEO at Relievant Can you tell us a bit about Relievant Medsystems and the Intracept® Procedure? Relievant is a venture-backed medical device company founded in 2006, based in Minneapolis and Sunnydale, California with around 45 employees. Our focus is currently shifting from [...]

2019-10-11T12:08:28+01:00June 12th, 2019|All News, Blog|

CeQur appoints Bradley Paddock Chief Executive Officer

CeQur appoints Bradley Paddock Chief Executive Officer Medical Device Veteran Has 23-Year Record of Successful Commercial and Organizational Leadership MARLBOROUGH, Mass., June 5, 2019 — CeQur® announced that the company has appointed Bradley Paddock as chief executive officer, effective today. Paddock brings a track record of commercial medtech successes, [...]

2019-10-10T09:39:28+01:00June 6th, 2019|All News, Blog|